Company: INTS
Filing Date: 2025-06-12
Form Type: 424B5
Source: 0001628280-25-031040
Chunk: 19

Company: INTENSITY THERAPEUTICS, INC.
Filing Date: 2025-06-12
Form: 424B5
Chunk 19
---
      |
| Pro forma net tangible book value per share as of March 31, 2025                                       |     | $ | 0.12 |     |   |      |
| Increase in pro forma net tangible book value per share attributable to new investors in this offering |     | $ | 0.02 |     |   |      |
| Pro forma as adjusted net tangible book value per share after this offering                            |     |   |      |     | $ | 0.14 |
| Dilution in net tangible book value per share to new investors in this offering                        |     |   |      |     | $ | 0.16 |

The foregoing discussion and table do not take into account further dilution to new investors that could occur upon the exercise of outstanding options or warrants having a per share exercise price less than the per share offering price to the public in this offering. In addition, we may choose to raise additional capital due to market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans. To the extent that additional capital is raised through the sale of equity or convertible debt securities, the issuance of these securities could result in further dilution to our stockholders.

The number of shares of common stock shown above to be outstanding after this offering is based on 15,264,869 shares outstanding as of March 31, 2025 plus 3,133,333 shares issued in April 2025, and excludes:

• 4,040,801 shares of common stock issuable upon the exercise of outstanding stock options with a weighted average exercise price of $4.10 per share;

• 8,308,229 shares of common stock issuable upon the exercise of outstanding warrants to purchase common stock with a weighted average exercise price of $1.70 per share; and

• 957,277 additional shares of the Common Stock reserved for future issuance under our equity incentive plans.

To the extent that outstanding stock options or warrants are exercised, you will experience further dilution. In addition, we may choose to raise additional capital due to market conditions or strategic considerations even if we

<div align='center'>S-13</div>

believe we have sufficient funds for our current or future operating plans. The issuance of these securities could result in further dilution for investors purchasing shares of common stock in this offering.

<div align='center'>S-14</div>

### DIVIDEND POLICY
We have never declared or paid any cash dividends on our